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FORORD 
Først og fremst vil jeg takke mine veiledere. Denne oppgave omhandler en del av et 
forskningsprosjekt ved Avdeling for nevropsykiatri og psykosomatisk medisin, Oslo 
Universitetssykehus, Rikshospitalet, om sykdomsmekanismer ved bipolar 2-lidelse. Torbjørn 
Elvsåshagen har med god veiledning og utmerkete pedagogiske evner hjulpet meg med å 
orientere meg innen dette felt. Uten Torbjørns innsats hadde det varit vanskelig å få oversikt 
innen faget på den begrensede tid som er satt av til prosjektoppgaven. Gjennom arbeidet med 
oppgaven har jeg fått god innsikt i et spennende felt som ligger i skjærningspunktet mellom 
psykiatri og nevrobiologi og gitt meg anledning til å øve på de forskjellige oppgaver som en 
forsker møter i sin hverdag. Jeg har arbeidet med prosjektplanlegging, innsamling av data, 
dataanalyse og skriftlig framstilling av resultatene. Jeg har sammen med veileder analysert 
data og vi har sammenfattet resultatene i denne prosjektoppgaven. Basert på denne oppgaven 
vil det utarbeides en artikkel som vil publiseres i et internasjonalt tidsskrift med 
fagfellevurdering. Prosjektoppgaven har gitt meg verdifull kunnskap som jeg tar med meg 
videre i karrieren, både innen det spesifikke faget som oppgaven beskriver, og mer generelle 
kunnskaper om prosessen kring medisinsk forskningsarbeid. 
 
Nils Olof Andreas Englin, Mars 2011 
  2
TABLE OF CONTENTS 
ABSTRACT............................................................................................................................................4 
INTRODUCTION ..................................................................................................................................5 
METHODS .............................................................................................................................................7 
Participants.........................................................................................................................................7 
Experimental paradigm ......................................................................................................................8 
Recording of the VEP..........................................................................................................................9 
Analysis of the VEP.............................................................................................................................9 
Statistical analyses............................................................................................................................10 
RESULTS .............................................................................................................................................10 
Demographic and clinical variables.................................................................................................10 
Plasticity of the VEP in healthy controls ..........................................................................................11 
Plasticity of the VEP in patients with BD-II .....................................................................................11 
Relationships between plasticity of the VEP and clinical variables .................................................12 
DISCUSSION.......................................................................................................................................12 
Investigations of neocortical plasticity in humans using repetitive sensory stimulation ..................13 
Does VEP plasticity reflect LTP? .....................................................................................................14 
Altered synaptic plasticity in mood disorders ...................................................................................14 
Altered synaptic plasticity in bipolar disorder..................................................................................15 
Impaired cortical plasticity in subjects with BD-II...........................................................................16 
Limitations ........................................................................................................................................16 
Conclusions.......................................................................................................................................17 
REFERENCES .....................................................................................................................................18 
TABLES ...............................................................................................................................................20 
FIGURES..............................................................................................................................................21 
  3
ABSTRACT 
Objective: It has recently been hypothesized that synaptic plasticity may play an important 
role in the pathophysiology and treatment of bipolar disorders. In this study, we aimed to 
induce and assess plastic modifications of evoked responses in the visual system of healthy 
controls. In addition, we aimed to examine whether this form of plasticity is altered in 
patients with bipolar II disorder (BD-II).  
 
Methods: Recordings of visually evoked potentials (VEPs) in healthy controls and BD-II 
patients. Clinical information was obtained using standardized questionnaires and interviews. 
 
Results: In healthy controls, a 10-minute modulation phase using checkerboard reversals (2 
Hz) resulted in significant plasticity of the VEP. The P1 and N1 peak as well as the P1-N1 
peak-to-peak amplitude were all significantly increased, of which we found the P1-N1 peak-
to-peak amplitude to be the most robust measure of the effect. In BD-II patients, no 
significant plasticity of the VEP was found. Comparing the healthy controls and patients, we 
found a significant group difference in the P1-N1 peak-to-peak plasticity. We found no 
significant correlations when exploring possible relationships between P1-N1 peak-to-peak 
plasticity and clinical variables in the patient group. 
 
Conclusions: These findings suggest that plasticity of the VEP is an accessible and robust 
method for assessing neocortical plasticity in the intact human brain. The current evidence 
supports the notion that VEP plasticity reflects a form of neocortical plasticity closely related 
to long-term potentiation. Patients with BD-II had impaired neocortical plasticity relative to 
healthy controls. Future studies should longitudinally assess plasticity of the VEP in BD-II 
before and after treatment.  
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INTRODUCTION 
Bipolar disorders are among the leading causes of disability worldwide.1, 2 Bipolar I disorder 
(BD-I), defined by manic episodes, affects approximately 1 % of the population, whereas 
bipolar II disorder (BD-II), characterized by recurrent episodes of depression and hypomania, 
has a prevalence between 1 and 2 %.3-5 Hypomanias are episodes of hyperactivity and 
elevated mood that are often overlooked both by patients and health workers because they 
seldom have negative consequences.5 In contrast, the manias of BD-I include psychotic 
symptoms and often severe malfunctioning.4 Clinical studies, family studies and genetic 
studies support that BD-II is a distinct disorder, separated from BD-I.6, 7 On several aspects, 
BD-II has the most severe natural course, with higher rates of suicide, comorbid alcoholism 
and anxiety disorders and more time spent in depressive episodes than BD-I.8, 9 BD-II is a 
highly heritable disorder with an estimated heritability of 60-80 %.6, 7  
Despite being common and important psychiatric illnesses, the exact 
pathophysiological mechanisms underlying bipolar disorders have not been fully clarified. In 
particular, the neurobiology of BD-II remains understudied. In recent years, it has been 
hypothesized that synaptic plasticity, the capacity of synapses for functional and structural 
change, may play an important role in the pathophysiology and treatment of bipolar 
disorders.10  
Synaptic plasticity mediates changes in the strength of synaptic transmission and in 
the interplay between neural networks.11-13 The best characterized forms of synaptic plasticity 
are long-term potentiation (LTP) and long-term depression (LTD), persistent increases and 
decreases in synaptic strength, respectively. In typical ex vivo studies of synaptic plasticity, 
LTP are induced by patterned, high-frequent stimulation, while LTD emerges after 
unpatterned, low-frequent stimulation.11-13 LTP and LTD are leading candidate mechanisms 
for learning and memory; it has been shown in rodent studies that hippocampal-dependent 
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learning induces hippocampal LTP14 and that reversal of LTP may erase a recently 
established memory.15   
In addition to the assumed role in learning and memory, there is a growing body of 
evidence implicating synaptic plasticity, e.g., LTP and LTD, in neuropsychiatric illnesses. It 
has been suggested that impaired synaptic plasticity may lead to aberrant communication in 
and between neural networks, and, consequently, abnormalities in complex behaviour and 
mood.10, 16 Hence, mood disorders have been conceptualized as diseases of synaptic plasticity 
in brain areas involved in mood regulation.10, 16 This notion is supported by rodent studies 
reporting that synaptic plasticity, e.g., LTP, is impaired in animal models of depression.10, 17 
Further, it has been found that antidepressants and mood stabilizers modulates synaptic 
plasticity in vitro17-19 and in vivo.20  
To date, there is a paucity of clinical evidence supporting the role of synaptic 
plasticity in mood disorders. Progress has been hindered by the challenging task that in vivo 
assessments of synaptic plasticity in the human brain represents. In recent years, however, 
plasticity of neocortical evoked responses after repeated sensory stimulation has been found 
in the living rodent and human brain.21-24 The plasticity of the cortical responses has been 
stimulus specific,23, 25 long-lasting,21, 25 and NMDA- and AMPA-receptor dependent,25, 26 
which are hallmarks of LTP. Further, it was recently reported that plasticity of the visual 
evoked potential (VEP) induced by repeated visual stimulation was reversed after infusion of 
ZIP, a peptide which have been shown to reverse LTP.27 Therefore, plasticity of evoked 
responses to sensory stimulation may represent an accessible method for studies of 
neocortical LTP in the intact human brain.  
Normann et al. assessed plasticity of VEPs among healthy controls and patients with 
major depressive disorder (MDD).28 They found a stimulus specific and long-lasting 
potentiation of early VEP components among healthy controls. In addition, they reported that 
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plasticity of the VEP was altered in subjects with MDD, thus providing the first in vivo 
evidence of impaired neocortical plasticity in MDD.28 To our knowledge, no study of 
neocortical plasticity in bipolar disorders has been published.  
In this study, we aimed to replicate plasticity of VEPs as a simple and reliable assay 
for studies of neocortical plasticity in the intact human brain. Based on previous results,17 we 
hypothesized that healthy controls would show plasticity of the P1 and the N1 peaks of the 
VEP. In addition, we aimed to examine plasticity of VEPs in subjects with BD-II. We 
hypothesized that subjects with BD-II would show altered plasticity of the VEP compared to 
healthy controls. In explorative analyses, we examined the relationships between VEP 
plasticity and clinical variables.   
 
METHODS 
Participants 
Twenty patients with BD-II (12 females, mean [SD] age, 33.7 [6.9] years) were recruited 
from psychiatric outpatient clinics in the Oslo area. Demographic and supplementary 
information was obtained using the Stanley Foundation Network Entry Questionnaire 
(NEQ).29 Axis I diagnoses and psychiatric comorbidities were determined using the Mini-
International Neuropsychiatric Interview (MINI), DSM-IV criteria version 5.0.30 The MINI 
was applied as a semi-structured interview to obtain optimal validity of the diagnoses. 
Alcohol and drug abuse were assessed with the Alcohol Use Scale and the Drug Use Scale31, 
respectively. Mood state was determined by the Montgomery–Asberg Depression Rating 
Scale (MADRS)32 and the Young Mania Rating Scale (YMRS).33  
Forty healthy controls (24 females, mean [SD] age, 31.1 [9.3] years) matched with the 
patient group for sex and age were recruited through local advertising and underwent a full 
  7
examination similar to that of the BD-II patients. Controls with previous or current 
psychiatric illness were excluded from the study.  
The exclusion criteria for all subjects were an age below 18 or above 50 years, 
previous head injury with loss of consciousness for over 1 minute, history of neurological or 
other severe chronic somatic disorder, and pregnancy. All subjects had normal or corrected-
to-normal visual acuity. The study was approved by the Regional Ethical Committee of 
South-Eastern Norway (REK Sør-Øst), and all subjects provided written informed consent to 
participate in the study.  
 
Experimental paradigm  
To enable comparisons with the previous study of VEP plasticity among healthy controls and 
subjects with MDD, the same experimental paradigm was used.28 In brief, VEPs were evoked 
by checkerboard reversals (check size = .5°; 2 reversals per second) in 2 baseline blocks 
before and 6 test blocks after a plasticity inducing modulation block, as shown in Figure 1. In 
each baseline and post-modulation test block, 40 checkerboard reversals were presented 
within 20 sec. The baseline blocks were performed 2 and 8 min after the start of the 
experiment. Two minutes after the last baseline block, checkerboard reversals (check size = 
.5°; 2 reversals per second) were presented for 10 minutes in the modulation block. Then, the 
post-modulation test blocks were performed 2, 8, 12, 18, 22, and 28 min after the end of the 
modulation block. In the intervals between checkerboard stimulation, a grey screen was 
displayed. The subjects were instructed to focus on a filled red circle (.1°) in the centre of the 
screen during the experiment and were allowed to listen to music.  
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Recording of the VEP 
Continuous electroencephalographic (EEG) activity was recorded from 15 monopolar 
Ag/AgCl electrodes according to the international 10–20 system. The ground and reference 
electrodes were attached to the forehead. Eye movements were recorded with bipolar 
electrodes placed at the sub- and supraorbital regions and at the lateral canthi of each eye. 
Impedances were kept below 5 kΩ. The EEG activity was sampled at 250 Hz with band pass 
filtering of 0.05–100 Hz. During the recordings of VEP, subjects were sitting .97 m from a 
Samsung Syncmaster 2493HM LCD screen. The visual stimuli was presented using E-Prime 
1.1 (Psychology Software Tools, Inc., Sharpsburg, PA, USA).    
 
Analysis of the VEP 
The EEG was high-pass filtered at 1 Hz, subjected to independent component analysis to 
isolate blink and eye movement-related activity, and divided into epochs starting 200 ms 
before and continuing 350 ms after the onset of each checkerboard reversal. Epochs 
containing blinks between -100 to 50 ms were discarded and any remaining blink or eye 
movement-related activity was removed by removing the associated independent components 
from the data. Subsequently, epochs with amplitudes exceeding +/- 50 μV were rejected. 
After artifact rejection, epochs were low-pass filtered at 30 Hz, then baseline-corrected (-100 
to 0), and averaged to block-specific VEPs. The VEP peaks were defined as the most 
negative or positive peak amplitudes over pre-defined latency ranges (C1: the most negative 
peak between 70 and 100 ms; P1:  the most positive peak between 100 and 140 ms; N1: the 
most negative peak between 130 and 180 ms). Since previous studies have found plasticity of 
both the P1 and the N1 amplitude,24, 28 we also computed the P1-N1 peak-to-peak amplitude 
as a possible overall measure of VEP plasticity. All amplitudes and latencies were obtained 
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from the Oz electrode at the occipital head and amplitudes were measured relative to the 100 
ms baseline.  
 
Statistical analyses 
All statistical analyses were conducted with SPSS, version 16.0 for Windows (SPSS, Inc., 
Chicago). A two-tailed p value <0.05 was considered significant. To test for differences in 
demographic and clinical variables between patients and healthy comparison subjects, 
Student’s t-tests and chi-square tests were performed for continuous and categorical 
variables, respectively. 
For analyses of VEP plasticity, peak amplitudes were used. There was no significant 
difference in the VEP amplitudes between the 2 baseline recordings and they were therefore 
combined in the analyses. The VEP amplitudes from the 6 post-modulation blocks were 
averaged as post-modulation VEP. Repeated-measures analysis of variance (ANOVA) was 
performed to compare baseline and post-modulation C1, P1, N1, and P1-N1 peak-to-peak 
amplitudes. Two-way ANOVAs with the factors Time (two levels: baseline, post-stimulation) 
and Group (two levels: BD-II, healthy control) were used to compare VEP plasticity in 
patients with BD-II and healthy controls. 
In explorative analyses of relationships between clinical variables and VEP plasticity, 
parametric correlation analyses and two-way ANOVAs were performed.  
 
RESULTS 
Demographic and clinical variables 
Demographic and clinical data for patients and healthy controls are presented in Table 1. No 
significant difference was found between the groups for sex or age. Five patients were 
euthymic (MADRS score < 11 and YMRS score < 8), 8 patients were mildly depressed 
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(MADRS score 11-20), 4 patients were moderately depressed (MADRS score 22-31), and 1 
patient was severely depressed (MADRS score = 35). Two patients were hypomanic (YMRS 
score 10-11). Twelve patients were rapid cyclers. Panic disorder and social phobia were 
frequent comorbid psychiatric disorders. None met the criteria for current alcohol or drug 
abuse. Six patients used lamotrigine, 9 patients were using antidepressants (escitalopram, 
bupropion, venlafaxine, mirtazapine, and sertraline), and 1 patient used a benzodiazepine 
(oxazepam). Nine patients were drug-free.  
 
Plasticity of the VEP in healthy controls  
Figure 2A shows baseline and post-modulation VEP from healthy controls. There was no 
significant effect of the modulation block on the C1 amplitude (F = .349; p = .558). In 
contrast, there was a significant effect of the modulation block on the P1 (F = 12.15; p = 
.001) and the N1 amplitude (F = 5.98; p = .019), that increased 39.4 % and 12.5 %, 
respectively (Figure 2B). Further, the most robust effect of the modulation block was found 
for the P1-N1 peak-to-peak amplitude (F = 47.71; p < .001), which increased 21.9 %. Figure 
3 shows the P1-N1 peak-to-peak at baseline and at the 6 post-modulation blocks.  
 
Plasticity of the VEP in patients with BD-II  
Figure 4A indicates baseline and post-modulation VEP among subjects with BD-II. In 
contrast to the VEP plasticity among healthy controls, there was no significant effect of the 
modulation block on the C1 (F = 1.73; p = .208), P1 (F = .25; p = .876), N1 (F = .54; p = 
.470), or the P1-N1 peak-to-peak amplitude (F =.95; p = .341) in the patient group (Figure 
4B). Next, we compared the effect of the modulation block on the VEP amplitudes in healthy 
controls and patients. There was a significant group difference in the plasticity of the P1-N1 
peak-to-peak amplitude (F =8.61; p = .005) and a trending difference in the plasticity of the 
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P1 amplitude (F =3.78; p = .057) (Figure 5). There was no significant difference in the 
modulation of the C1 (F =2.11; p = .648) or the N1 (F =.53; p = .470) amplitudes between 
the two groups.  
 
Relationships between plasticity of the VEP and clinical variables 
We used the P1-N1 peak-to peak, the measure that showed the most robust plasticity among 
healthy controls, to examine relationships between plasticity of the VEP and clinical 
variables in the patient group. There was no significant correlation between the depression 
severity as measured by the MADRS score and the plasticity of the P1-N1 peak-to peak (r = -
.08; p = .736). Further, we found no significant difference in the plasticity of the VEP 
between medicated and drug-free patients (F =.56; p = .466). In addition, drug-free patients 
had significantly reduced plasticity of the P1-N1 peak-to-peak compared to the healthy 
controls (F = 8.71; p = .005).  
 Next, we assessed the relationships between plasticity of the P1-N1 peak-to-peak and 
illness duration and lifetime number of depressive episodes. There was no significant 
association between plasticity of the P1-N1 peak-to-peak and illness duration (r = -.11; p = 
.661) or lifetime number of depressive episodes (r = .003; p = .990).  
 
DISCUSSION 
In this study, we aimed to replicate plasticity of the VEP as a simple and reliable assay for 
studies of neocortical plasticity in the intact human brain. In addition, we aimed to assess 
VEP plasticity in BD-II. We found that repetitive visual stimulation induced long-lasting 
plasticity of the VEP in healthy controls. Further, subjects with BD-II had impaired plasticity 
of the VEP compared with the control group. We found no significant associations between 
plasticity of the VEP and clinical variables in the patient group. 
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Investigations of neocortical plasticity in humans using repetitive sensory stimulation 
Current evidence suggests that plasticity of evoked responses to sensory stimulation may 
represent a simple and accessible method for studies of neocortical plasticity in the intact 
human brain. The first demonstration of plasticity of evoked potentials in living humans was 
provided by Teyler et al.24 They found that rapid (9Hz) repetitive presentation of a visual 
checkerboard led to a persistent potentiation of the N1 peak of the VEP. In a follow-up study, 
the specificity of the potentiation was tested using sine gratings with different spatial 
frequencies.23 It was found that the observed plasticity was stimulus-specific, suggesting that 
the potentiation effect was isolated to a discrete neural population in the visual cortex. Thus, 
the findings indicated that plasticity of the VEP was not the result of changes in overall brain 
excitability. In a later study, plasticity of the human auditory evoked potential after repeated 
auditory stimulation was observed,21 indicating that LTP-like plasticity after repetitive 
sensory stimulation may be a general trait of the human adult sensory cortex.  
 Normann et al. tested the dependency of VEP plasticity on the checkerboard reversal 
frequency.28 They found that two reversals per second produced the most robust plasticity of 
the VEP. 2 Hz checkerboard reversal stimulation led to a long-lasting plasticity of the P1 and 
N1, but not the C1 peak of the VEP among healthy controls.  
In this study, we replicated these findings in a larger sample of healthy volunteers. We 
found that prolonged 2 Hz checkerboard reversal stimulation led to significant potentiation of 
the P1 and the N1 amplitudes. In parallel to previous findings,28 we did not find any 
significant changes in the C1 peak. Further, as the previous and our study found plasticity of 
both the P1 and the N1 amplitude, we assessed the P1-N1 peak-to-peak plasticity as a 
measure of the overall plasticity of the VEP. We found that the plasticity of the P1-N1 peak-
to-peak was more robust than plasticity of the P1 or the N1 peak alone. Therefore, we suggest 
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that P1-N1 peak-to-peak plasticity can be used in future studies as an overall measure of VEP 
plasticity.  
 
Does VEP plasticity reflect LTP? 
The mechanisms underlying the plasticity of the VEP in the intact brain have been explored 
in recent studies. It has been shown that plasticity of the VEP is stimulus-specific,23, 25, 28 
long-lasting,24, 25 and NMDA- and AMPA-receptor dependent,26, 27 which are hallmarks of 
LTP. Further, a recently published study found that plasticity of VEPs was reversed after 
infusion of ZIP,27 a peptide shown to reverse LTP.15 In addition, it was reported that cortical 
LTP, induced by tetanic thalamocortical stimulation, and plasticity of the VEP induced by 
repetitive visual stimulation mutually occluded each other.27 Thus, the current evidence 
supports the notion that VEP plasticity reflects a form of neocortical plasticity closely related 
to LTP.  
 
Altered synaptic plasticity in mood disorders 
In recent years, research in bipolar disorders and mood disorders in general has moved away 
from focusing on absolute changes in neurochemicals and instead has begun highlighting the 
role of synapses and neural networks and the plastic processes controlling their functioning.10, 
16 The network hypothesis of mood disorders proposes that impaired synaptic plasticity and 
neural communication in and between areas involved in mood regulation, e.g., anterior 
cingulate, prefrontal cortex, the amygdale, and the hippocampus, may underlie mood 
dysregulation.10, 16 In support of this hypothesis, disturbed synaptic plasticity and loss of 
synapses have been found in animal models of depression. Holderbach et al. found that 
chronic mild stress led to altered LTD in the hippocampal CA1 region.17 Further, chronic 
treatment with an antidepressant normalized the LTD and facilitated the induction of LTP.17 
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Hajszan et al. reported that the rat learned helplessness model of depression was associated 
with loss of hippocampal synapses.34 Notably, loss of synapses was prevented by 
antidepressant treatment. Another study found that chronic treatment with fluoxetine, an 
SSRI, increased synaptic plasticity in the adult rat visual cortex.20 Further, a recent study 
found that synapse formation in the prefrontal cortex may underlie the antidepressant effects 
of NMDA-receptor antagonists in rats.35 Thus, rodent studies suggest that mood disorders are 
associated with disturbed functional and structural synaptic plasticity and that treatment with 
antidepressants may prevent or reverse these impairments.  
 
Altered synaptic plasticity in bipolar disorder 
To date, the evidence supporting the role of synaptic plasticity in the pathophysiology of 
bipolar disorders mainly comes from post mortem studies and in vitro examinations of the 
effects of mood stabilizers. One study found that the expression of vesicular glutamate 
transporter 1 (VGluT1) and netrin-G1 and netrin-G2, markers of glutamate synaptic 
transmission and plasticity, was altered in the anterior cingulate cortex from subjects with 
bipolar disorder.36 Another study reported that synaptic markers were reduced in visual 
association cortex in bipolar disorder.37 A third study found that the level of GAP-43, a 
putative neuronal plasticity marker, was significantly reduced among subjects with bipolar 
disorders relative to control subjects.38 Turning to the effects of mood stabilizers, it has been 
shown that acute and chronic lithium treatment may enhance LTP in the rat hippocampus ex 
vivo.18, 39 Furthermore, treatment of rats with lithium and valproate have been shown to 
modulate hippocampal synaptic AMPA-receptor levels.19  
Together, these findings suggest that synaptic plasticity may play an important role in 
bipolar disorders and other mood disorders. There is, however, a paucity of clinical evidence 
supporting these novel hypotheses.  
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Impaired cortical plasticity in subjects with BD-II 
Despite the hypothesis of impaired synaptic plasticity in mood disorders, no study assessing 
cortical plasticity in bipolar disorders has been published. In this study, we found that BD-II 
was associated with impaired cortical plasticity. In contrast to the significant plasticity of the 
VEP among healthy controls, no significant plasticity was observed among subjects with BD-
II. Further, there was a significant difference in plasticity of the VEP between healthy 
controls and subjects with BD-II. Thus, this is the first study providing evidence for impaired 
neocortical plasticity in bipolar disorder. Although the exact mechanisms remain to be 
clarified, we speculate that impaired synaptic plasticity underlies these findings.  
 We did not find any relationships between plasticity of the VEP and depression 
severity, illness duration or lifetime number of depressive episodes in patients. Moreover, 
there was no significant difference in plasticity of the VEP between medicated and 
unmedicated subjects with BD-II. Thus, these findings may suggest that impaired neocortical 
plasticity is a stable trait among subjects with BD-II. 
 
Limitations 
This study had several limitations. One important limitation is the relatively modest size of 
the patient group which may have reduced the statistical power to detect significant 
relationships between clinical variables and plasticity of the VEP. Further, because of the 
cross-sectional design of the study, we cannot firmly decide whether impaired cortical 
plasticity in BD-II is mood-dependent or a stable trait of this disorder. Thus, future studies 
should longitudinally assess plasticity of the VEP during mood episodes and in euthymia. 
Moreover, we included both medicated and unmedicated patients with BD-II. We did not find 
any significant difference in plasticity of the VEP between medicated and drug-free patients. 
In addition, also drug-free patients had reduced plasticity of the VEP compared to healthy 
controls. These findings suggest that medication does not underlie the differences in the 
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plasticity of the VEP between subjects with BD-II and healthy controls. Nevertheless, future 
studies should assess plasticity of the VEP in BD-II before and after medication.  
 
Conclusions 
In this study, we replicated plasticity of the VEP in healthy controls. Thus, plasticity of the 
VEP may be a robust and accessible method for studies of neocortical plasticity in the intact 
human brain. In addition, we found that subjects with BD-II had impaired cortical plasticity 
relative to healthy controls. To our knowledge, these findings represent the first direct 
evidence for impaired neocortical plasticity in bipolar disorders. Future studies should 
longitudinally assess plasticity of the VEP in BD-II before and after treatment.   
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TABLES 
TABLE 1. Demographic and Clinical Characteristics of Patients With Bipolar II 
Disorder and Healthy Controls 
Characteristic 
Bipolar II Group 
(N=20)  
Healthy Controls 
(N=40) Analysis 
 
 Mean  SD Mean  SD 
 
p 
Age (years) 33.7  6.9 31.1  9.3 .28 
Montgomery-Asberg Depression 
Rating Scale score 16.3 8.9 1.0 0.9 
 
<.001 
Young Mania Rating Scale score 2.7  3.0 0.3  0.8 
 
<.001 
Duration of illness (years) 18.1  7.0 
  
 
Lifetime number of depressive 
episodesa 27.9 21.7 
  
 
  
N 
 
% 
 
 
N 
 
 
% 
 
 
p 
Female 12 60 24 60 
 
Rapid cycling 12  60    
Social phobia 5  25    
Panic disorder 8 40    
General anxiety disorder 1  5    
 
a Missing for two subjects 
 
 
 
 
  20
FIGURES 
FIGURE 1. Experimental Setup  
 
 
 
 
FIGURE 2A. Baseline and Post-modulation VEP among Healthy Controls 
 
 
 
 
 
  21
FIGURE 2B. Plasticity of the VEP in Healthy Controls  
 
 
 
n.s; not significant 
* p = .019 
** p = .001  
*** p < .001 
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FIGURE 3. The P1-N1 Peak-to-peak Amplitude at Baseline and Post-modulation Blocks 
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FIGURE 4A. Baseline and Post-modulation VEP among Patients With BD-II 
 
 
 
FIGURE 4B. Plasticity of the VEP in Patients With BD-II 
 
 
n.s; not significant 
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FIGURE 5. Plasticity of the VEP Among Healthy Controls and Subjects With BD-II 
 
 
 
n.s; not significant 
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